The Role of CCL24 in Primary Sclerosing Cholangitis: Bridging Patient Serum Proteomics to Preclinical Data
Cells · 2024
DOI: 10.3390/cells13030209 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Raanan Greenman und 13 weiteren Autor:innen. Beteiligte Einrichtung: Chemomab Therapeutics Ltd., Tel Aviv 6158002, Israel. Hauptthemen laut MEDLINE: Cholangitis, Sclerosing, Cholestasis. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chemomab Therapeutics Ltd..
Abstract (Originalsprache)
Primary sclerosing cholangitis (PSC) is an inflammatory and fibrotic biliary disease lacking approved treatment. We studied CCL24, a chemokine shown to be overexpressed in damaged bile ducts, and its involvement in key disease-related mechanisms. Serum proteomics of PSC patients and healthy controls (HC) were analyzed using the Olink® proximity extension assay and compared based on disease presence, fibrosis severity, and CCL24 levels. Disease-related canonical pathways, upstream regulators, and toxicity functions were elevated in PSC patients compared to HC and further elevated in patients with high CCL24 levels. In vitro, a protein signature in CCL24-treated hepatic stellate cells (HSCs) differentiated patients by disease severity. In mice, CCL24 intraperitoneal injection selectively recruited neutrophils and monocytes. Treatment with CM-101, a CCL24-neutralizing antibody, in an α-naphthylisothiocyanate (ANIT)-induced cholestasis mouse model effectively inhibited accumulation of peribiliary neutrophils and macrophages while reducing biliary hyperplasia and fibrosis. Furthermore, in PSC patients, CCL24 levels were correlated with upregulation of monocyte and neutrophil chemotaxis pathways. Collectively, these findings highlight the distinct role of CCL24 in PSC, influencing disease-related mechanisms, affecting immune cells trafficking and HSC activation. Its blockade with CM-101 reduces inflammation and fibrosis and positions CCL24 as a promising therapeutic target in PSC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chemomab Therapeutics Ltd., Tel Aviv 6158002, Israel.
- Goldyne Savad Institute of Gene Therapy, Hebrew University Hospital Jerusalem, Jerusalem 91120, Israel.
- UCL Institute for Liver and Digestive Health, University College of London, London NW3 2PF, UK.
- Sheila Sherlock Liver Centre, Royal Free London NHS Foundation Trust, London NW3 2QG, UK.
- Department of Gastroenterology and Hepatology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK.
ORCID-Profile: Raanan Greenman, Matthew Frankel, Francesca Saffioti
Förderung
- Chemomab Therapeutics Ltd.
Zitieren
APA
Greenman, R., Snir, T., Katav, A., Aricha, R., Mishalian, I., Hay, O., Frankel, M., Lawler, J., Saffioti, F., Pinzani, M., Thorburn, D., Peled, A., Mor, A., & Vaknin, I. (2024). The Role of CCL24 in Primary Sclerosing Cholangitis: Bridging Patient Serum Proteomics to Preclinical Data. Cells. https://doi.org/10.3390/cells13030209
Vancouver
Greenman R, Snir T, Katav A, Aricha R, Mishalian I, Hay O, et al. The Role of CCL24 in Primary Sclerosing Cholangitis: Bridging Patient Serum Proteomics to Preclinical Data. Cells. 2024. doi:10.3390/cells13030209
BibTeX
@article{Greenman2024,
author = {Greenman, Raanan and Snir, Tom and Katav, Avi and Aricha, Revital and Mishalian, Inbal and Hay, Ophir and Frankel, Matthew and Lawler, John and Saffioti, Francesca and Pinzani, Massimo and Thorburn, Douglas and Peled, Amnon and Mor, Adi and Vaknin, Ilan},
title = {The Role of CCL24 in Primary Sclerosing Cholangitis: Bridging Patient Serum Proteomics to Preclinical Data},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13030209}
}
EUVIMED